会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Quinuclidine derivatives as substance P antagonists
    • 奎宁环衍生物作为物质P拮抗剂
    • US5569662A
    • 1996-10-29
    • US313289
    • 1994-10-03
    • Kunio SatakeHiroaki WakabayashiMasami Nakane
    • Kunio SatakeHiroaki WakabayashiMasami Nakane
    • C07D453/02A61K31/445
    • C07D453/02
    • Compounds useful in the treatment of inflammatory disorders, central nervous system disorders and other disorders of formula (I) and the pharmaceutically-acceptable salts thereof, wherein X.sup.1 is alkoxy or halosubstituted alkoxy; X.sup.2 is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, halosubstitued alkyl, halosubstituted alkoxy, alkylamino, dialkylamino, alkylsulfonylamino (which may be substituted), N-alkyl-N-alkylsulfonylamino (which may be substituted), alkanoylamino (which may be substituted) or N-alkyl-N-alkanoylamino (which may be substituted); Ar.sup.1 and Ar.sup.2 are each, independently, thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl; A is Y--(CH.sub.2).sub.m --CH(R.sup.2)--(CH.sub.2).sub.n --NR.sup.1 --; R.sup.1 is hydrogen, alkyl, benzyl or --(CH.sub.2).sub.p --Y; R.sup.2 is hydrogen, alkyl (which may be substituted), benzyl, 4-hydroxybenzyl, 3-indolylmethyl or --(CH.sub.2).sub.p --Y; Y is --CN, --CH.sub.2 Z or --COZ; Z is hydroxy, amino, alkoxy, alkylamino or dialkylamino; m, n and p are each, independently, 0, 1, 2 or 3; and R.sup.1 and R.sup.2 may be connected to form a ring.
    • PCT No.PCT / US93 / 01810 Sec。 371日期:1994年10月3日 102(e)日期1994年10月3日PCT 1993年3月5日PCT公布。 WO93 / 19064 PCT公开号 日期1993年9月30日可用于治疗炎症性疾病,中枢神经系统疾病和式(I)的其它病症及其药学上可接受的盐的化合物,其中X1是烷氧基或卤代取代的烷氧基; X 2是氢,卤素,烷基,烯基,炔基,烷氧基,烷硫基,烷基亚磺酰基,烷基磺酰基,卤素取代的烷基,卤代烷氧基,烷基氨基,二烷基氨基,烷基磺酰基氨基(其可被取代的),N-烷基-N-烷基磺酰基氨基 ),烷酰基氨基(其可以被取代)或N-烷基-N-烷酰基氨基(其可以被取代); Ar1和Ar2各自独立地为噻吩基,苯基,氟苯基,氯苯基或溴苯基; A是Y-(CH 2)m -CH(R 2) - (CH 2)n -NR 1; R1是氢,烷基,苄基或 - (CH2)p-Y; R 2是氢,烷基(其可以被取代),苄基,4-羟基苄基,3-吲哚基甲基或 - (CH 2)p-Y; Y是-CN,-CH2Z或-COZ; Z是羟基,氨基,烷氧基,烷基氨基或二烷基氨基; m,n和p各自独立地为0,1,2或3; 并且R1和R2可以连接形成环。
    • 5. 发明授权
    • Substituted quinuclidines as substance P antagonists
    • 取代的奎宁化合物作为P物质拮抗剂
    • US5837711A
    • 1998-11-17
    • US428240
    • 1995-04-28
    • Fumitaka ItoToshihide KokuraMasami NakaneKunio SatakeHiroaki Wakabayashi
    • Fumitaka ItoToshihide KokuraMasami NakaneKunio SatakeHiroaki Wakabayashi
    • C07D453/02A61K31/44
    • C07D453/02
    • Certain novel substituted quinuclidine compounds having the ability to antagonize substance P and having the following formula: ##STR1## wherein Ar.sup.1 and Ar.sup.2 are each, independently, thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl; X is --CONR.sup.3 R.sup.4, --CO.sub.2 R.sup.3, --CH.sub.2 OR.sup.3, --CH.sub.2 NR.sup.3 R.sup.4 or --CONR.sup.3 OR.sup.4 ; R.sup.1, R.sup.3 and R.sup.4 are each, independently, hydrogen or alkyl having 1 to 4 carbon atoms; R.sup.2 is alkyl having 1 to 4 carbon atoms; Y is alkylsulfonyl having 1 to 4 carbon atoms, N-alkyl-N-alkanoylamino (which may be substituted by halogen in the alkanoyl moiety) having 1 to 4 carbon atoms in the alkyl and the alkanoyl moieties, N-alkyl-N-alkylsulfonylamino (which may be substituted by halogen in the alkylsulfonyl moiety) having 1 to 4 carbon atoms in the alkyl and the alkyl sulfonyl moieties, alkenyl having 2 to 4 carbon atoms, alkynyl having 2 to 4 carbon atoms, halosubstituted alkyl having 1 to 4 carbon atoms, alkylamino having 1 to 4 carbon atoms, alkanoylamino (which may be substituted by halogen) having 1 to 4 carbon atoms or alkylsulfonylamino (which may be substituted by halogen) having 1 to 4 carbon atoms. These compounds are useful in the treatment gastrointestinal or central nervous system disorders and the alleviation of inflammatory diseases, asthma, pain and migraine in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.
    • PCT No.PCT / US93 / 09169 Sec。 371日期:1995年4月28日 102(e)日期1995年4月28日PCT 1993年9月30日PCT公布。 出版物WO94 / 10170 日期:1994年5月11日具有拮抗物质P并具有下式的新颖取代的奎宁环化合物:其中Ar 1和Ar 2各自独立地为噻吩基,苯基,氟苯基,氯苯基或溴苯基; X是-CONR 3 R 4,-CO 2 R 3,-CH 2 OR 3,-CH 2 NR 3 R 4或-CONR 3 OR 4; R 1,R 3和R 4各自独立地为氢或具有1至4个碳原子的烷基; R2是具有1至4个碳原子的烷基; Y是具有1至4个碳原子的烷基磺酰基,在烷基和烷酰基部分中具有1至4个碳原子的N-烷基-N-烷酰基氨基(其可被烷酰基部分中被卤素取代)为N-烷基-N-烷基磺酰基氨基 (其可以被烷基磺酰基部分中的卤素取代)在烷基和烷基磺酰基部分中具有1至4个碳原子,具有2至4个碳原子的烯基,具有2至4个碳原子的炔基,具有1至4个碳原子的卤代烷基 原子,具有1至4个碳原子的烷基氨基,具有1至4个碳原子的烷酰基氨基(其可以被卤素取代)或具有1至4个碳原子的烷基磺酰基氨基(可被卤素取代)。 这些化合物可用于治疗哺乳动物的胃肠道或中枢神经系统疾病和减轻炎性疾病,哮喘,疼痛和偏头痛,并用作用于治疗这些病症的药物组合物中的活性成分。
    • 8. 发明授权
    • Substituted benzylaminopiperidine compounds
    • 取代的苄基氨基哌啶化合物
    • US06506775B1
    • 2003-01-14
    • US09564398
    • 2000-05-01
    • Kunio SatakeYuji ShishidoHiroaki Wakabayashi
    • Kunio SatakeYuji ShishidoHiroaki Wakabayashi
    • C07D21156
    • C07D211/56
    • The invention provides a compound of formula (I): and its pharmaceutically acceptable salts, wherein R is halo C2-C8 alkenyl or halo C2-C8 alkynyl; R1 is hydrogen, halo or C1-C6 alkoxy; or R and R1, together with the two carbon atoms to which they are attached, form a C4-C6 cycloalkyl or a C4-C6 oxacycloalkyl ring wherein said ring may be optionally substituted by one or more substituents selected from the group consisting of halo, C1-C6 alkyl and halo C1-C6 alkyl; X is C1-C6 alkoxy, halo C1-C6 alkoxy, phenoxy or halo; and Ar is phenyl optionally substituted by halo. These compounds are useful in the treatment of a gastrointestinal disorder; a central nervous system (CNS) disorder; an inflammatory disease; emesis; urinary incontinence; pain; migraine; sunburn; diseases, disorders and adverse conditions caused by Heliobacter pylori; or angiogenesis especially CNS disorders in a mammalian subject, especially humans.
    • 本发明提供式(I)化合物及其药学上可接受的盐,其中R为卤代C 2 -C 8烯基或卤代C 2 -C 8炔基; R 1为氢,卤素或C 1 -C 6烷氧基;或R和R 1与 它们连接的两个碳原子形成C 4 -C 6环烷基或C 4 -C 6氧杂环烷基环,其中所述环可任选地被一个或多个选自卤素,C 1 -C 6烷基和卤代C 1 -C 6烷基的取代基取代, C6烷基; X是C1-C6烷氧基,卤代C1-C6烷氧基,苯氧基或卤代; 并且Ar是任选被卤素取代的苯基。这些化合物可用于治疗胃肠道疾病; 中枢神经系统(CNS)障碍; 炎性疾病; 呕吐 尿失禁 疼痛; 偏头痛 晒斑; 由幽门螺杆菌引起的疾病,病症和不良状况; 或血管发生,尤其是哺乳动物受试者尤其是人类的CNS疾病。
    • 10. 发明授权
    • Benzyloxyquinuclidines as substance P antagonists
    • 作为P物质拮抗剂的苄氧基亚奎宁
    • US5869499A
    • 1999-02-09
    • US637682
    • 1996-03-03
    • Kunio SatakeHiroaki Wakabayashi
    • Kunio SatakeHiroaki Wakabayashi
    • A61K31/435A61P1/00A61P1/08A61P11/00A61P25/00A61P25/04A61P25/06A61P29/00A61P37/08C07D453/02A61K31/44C07D401/00
    • C07D453/02
    • A compound of chemical formula (I) and its pharmaceutically acceptable salt: ##STR1## wherein X and Y are each hydrogen, halogen, C.sub.1 -C.sub.6 alkyl, halosubstituted C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 alkylsulfinyl, C.sub.1 -C.sub.6 alkylsulfonyl, or tri(C.sub.1 -C.sub.6 alkyl)silyl; Ar.sup.1 and Ar.sup.2 are each independently aryl or heteroaryl, optionally substituted by halogen; A is --CO-- or -(CH.sub.2)-; Z-A- is at the 2 or 3 position on the quinuclidine ring; and Z is --OH, C.sub.1 -C.sub.6 alkoxy, NR.sup.1 R.sup.2 or the like. Representative compounds are (3S,4R,5S,6S)-5-�3,5-bis(trifluoromethyl)-benzyloxy!-N,N-dimethyl-6-diphenylmethyl-1-azabicyclo�2.2.2!octan-3-carboxamide, and -3-carboxylic acid. These novel benzyloxyquinuclidines are active as substance P receptor antagonists and are thus useful for treating gastrointestinal disorders, central nervous system disorders, allergy, inflammatory diseases, asthma, pain, emesis, migraine, urinary incontinence, or angiogenesis in mammals, especially humans.
    • PCT No.PCT / JP94 / 01092 Sec。 371日期1996年3月3日 102(e)1996年3月3日PCT 1994年7月5日PCT公布。 出版物WO95 / 02595 日期1995年1月26日化学式(I)化合物及其药学上可接受的盐:其中X和Y各自为氢,卤素,C 1 -C 6烷基,卤素取代的C 1 -C 6烷基,C 1 -C 6烷氧基, C 1 -C 6烷基硫基,C 1 -C 6烷基亚磺酰基,C 1 -C 6烷基磺酰基或三(C 1 -C 6烷基)甲硅烷基; Ar1和Ar2各自独立地为任选被卤素取代的芳基或杂芳基; A是-CO-或 - (CH 2) - ; Z-A-位于奎宁环上2或3位; Z为-OH,C1-C6烷氧基,NR1R2等。 代表性的化合物是(3S,4R,5S,6S)-5- [3,5-双(三氟甲基) - 苄氧基] -N,N-二甲基-6-二苯基甲基-1-氮杂双环[2.2.2] 甲酰胺和-3-羧酸。 这些新型的苄氧基奎宁类作为物质P受体拮抗剂是有活性的,因此可用于治疗哺乳动物,特别是人类的胃肠疾病,中枢神经系统疾病,变态反应,炎性疾病,哮喘,疼痛,呕吐,偏头痛,尿失禁或血管生成。